Aptargroup

ATR · NYSE

$125.77+$1.14 (+0.91%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $124.63

ATR analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 9 analysts

Average $172.17 (+36.9% upside)

Low: $156.11
Now: $125.77
High: $231.00

Upgrades and downgrades

The latest rating actions, newest first

ATR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 9, 2026	Initiates	Neutral	$135.00	29%
Wells Fargo	Aug 3, 2026	Maintains	Overweight	$145.00 → $155.00	51%
Wells Fargo	May 4, 2026	Maintains	Overweight	$144.00 → $145.00	51%
Wells Fargo	Mar 20, 2026	Upgrade	Equal-Weight → Overweight	$133.00 → $144.00	51%
Wells Fargo	Jan 6, 2026	Downgrade	Overweight → Equal-Weight	$133.00	51%
Wells Fargo	Nov 3, 2025	Maintains	Overweight	$152.00 → $133.00	51%
Baird	Nov 3, 2025	Maintains	Outperform	$160.00 → $145.00	55%

The case for and against

Updated Feb 9, 2026

Bull case

AptarGroup has demonstrated significant growth potential through its AMS Solutions segment, which has achieved a compound annual growth rate (CAGR) of approximately 10%, accounting for around 11% of Pharma's revenue and 5% of total revenue for FY24. The company is also benefiting from the increasing demand for injectable products, driven by a global shift towards biologics and a focus on GLP-1 drugs, with this segment experiencing a growth rate of 9% CAGR. This robust demand, paired with AptarGroup's capacity to meet it, is expected to support continued margin expansion and enhance overall profitability.

Bear case

AptarGroup faces significant risks that could adversely affect its stock performance, primarily stemming from the prolonged transition to a majority Pharma focus, which may hinder anticipated growth and margin expansion. Additionally, the company's global operations expose it to currency fluctuations, economic cycles, and regulatory challenges, all of which can impact demand and revenue stability. Furthermore, ongoing trade tensions and the potential for intellectual property issues could further weaken competitive advantages and consumer confidence, compounding the already present challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.